- Home
- HBNC vs GALT Comparison
HBNC vs GALT Comparison
Compare HBNC & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBNC
- GALT
- Stock Information
- Founded
- HBNC 1873
- GALT 2000
- Country
- HBNC United States
- GALT United States
- Employees
- HBNC N/A
- GALT N/A
- Industry
- HBNC Major Banks
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- HBNC Finance
- GALT Health Care
- Exchange
- HBNC Nasdaq
- GALT Nasdaq
- Market Cap
- HBNC 706.4M
- GALT 232.3M
- IPO Year
- HBNC N/A
- GALT N/A
- Fundamental
- Price
- HBNC $16.25
- GALT $5.37
- Analyst Decision
- HBNC Buy
- GALT Strong Buy
- Analyst Count
- HBNC 3
- GALT 3
- Target Price
- HBNC $19.67
- GALT $6.00
- AVG Volume (30 Days)
- HBNC 526.3K
- GALT 310.7K
- Earning Date
- HBNC 10-22-2025
- GALT 11-12-2025
- Dividend Yield
- HBNC 3.94%
- GALT N/A
- EPS Growth
- HBNC 170.74
- GALT N/A
- EPS
- HBNC 1.17
- GALT N/A
- Revenue
- HBNC $211,582,000.00
- GALT N/A
- Revenue This Year
- HBNC $47.63
- GALT N/A
- Revenue Next Year
- HBNC $4.03
- GALT N/A
- P/E Ratio
- HBNC $13.89
- GALT N/A
- Revenue Growth
- HBNC 19.27
- GALT N/A
- 52 Week Low
- HBNC $12.70
- GALT $0.73
- 52 Week High
- HBNC $19.18
- GALT $6.55
- Technical
- Relative Strength Index (RSI)
- HBNC 50.66
- GALT 68.40
- Support Level
- HBNC $16.06
- GALT $3.93
- Resistance Level
- HBNC $17.02
- GALT $4.35
- Average True Range (ATR)
- HBNC 0.37
- GALT 0.38
- MACD
- HBNC -0.04
- GALT 0.10
- Stochastic Oscillator
- HBNC 47.26
- GALT 55.47
About HBNC Horizon Bancorp Inc.
Horizon Bancorp (IN) is a United States-based holding company providing banking services. It is engaged in providing commercial and retail banking services, corporate and individual trust and agency services, and other services incident to banking. The company also provides commercial loans, real estate loans, mortgage warehouse loans, consumer loans, and other credit facilities. The company has one principal business segment, commercial banking.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.